Immunomedics, Inc. (IMMU): Analyst Phil Nadeau Provides Update From San Antonio Breast Cancer Symposium

Immu-132 continues to have strong efficacy in centrally-reviewed data at SABCS, says Cowen’s Phil Nadeau.

Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract

Immunomedics, Inc. (NASDAQ:IMMU) left investors worried about its cancer asset IMMU-132 after revealing an abstract at yesterday’s annual San Antonio Breast Cancer Symposium¬† …

Here’s Why This Analyst Is Not Counting Immunomedics, Inc. (IMMU) Out of Approval in mTNBC Despite Disappointing SABCS Abstract

Cowen places more importance on ORR strength than reduction in OS for IMMU’s prospects for a green light.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts